Results 51 to 60 of about 847 (163)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine

Discoveries, 2023
Advancements in molecular biology and neuroscience have uncovered calcitonin gene-related peptide (CGRP), a neuropeptide consisting of thirty-seven amino acids that plays a crucial role in migraine pathogenesis. CGRP receptor antagonist or gepant is an oral medication that can impede the nociceptive signaling pathway related to CGRP.
Chowdhury, Selia, Dave, Tirth
openaire   +2 more sources

Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment (MIND) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to describe the real‐world diagnosis and treatment patterns of individuals newly diagnosed with migraine in the United States (US). Background Over 10% of adults in the US are living with migraine.
Fred Cohen, Vincent Martin, Avani Patel, Shelby L. Corman, Katie B. Tellor, Meghan Fajardo, D. Cortney Hayflinger, Simon Dagenais   +7 more
wiley   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

2‐Chloro‐5‐(trifluoromethyl)aniline‐Derived Schiff Base Palladium(II) Complexes: From Molecular Design to Acute Toxicity Assessment

ChemistryOpen, Volume 15, Issue 10, October 2026.
Four new Schiff bases derived from 2‐chloro‐5‐(trifluoromethyl)aniline and their corresponding palladium(II) complexes were obtained and analyzed by multiple spectroscopic techniques. Single‐crystal X‐ray diffraction elucidated the structures of all the ligands and complexes 2 and 4. Their toxicity was assessed on Triticum aestivum L.
Andreea Elena Ştefan, Cristina Elena Dinu‐Pîrvu, Sergiu Shova, Ştefania Felicia Bărbuceanu, Teodora Venera Apostol, Diana Carolina Ilieş, Mihaela Badea, Mihaela Dinu, Robert Viorel Ancuceanu, Doina Drăgănescu, Elena Pahonţu   +10 more
wiley   +1 more source

Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review

Headache: The Journal of Head and Face Pain, Volume 66, Issue 9, Page 2138-2155, October 2026.
Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland, Samuel J. Belfer, Christine K. Fox, Samantha L. Irwin, Rachel Vassar, Ann Oh, Sruthi Ilangovan, Amy A. Gelfand   +7 more
wiley   +1 more source

Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment

MedComm, Volume 7, Issue 9, September 2026.
Migraine is a highly prevalent, female‐predominant, and disabling brain disorder shaped by genetic susceptibility, hormonal influences, modifiable attack factors, and comorbidity‐related progression. This review integrates current evidence on migraine epidemiology, phase‐specific neurovascular and neuroglial mechanisms, including CGRP signaling and ...
Weiwei Lu, Yuan Zhang, Chen Shi, Yu Tao, Shaoxin Li, Yufang Sun, Fuhai Ji, Dongsheng Jiang, Terrance P. Snutch, Jin Tao   +9 more
wiley   +1 more source

Progress in treating migraines: promising prospects for a better tomorrow

Bulletin of the National Research Centre, 2023
Background Migraine is a debilitating disorder that undoubtedly has a significant impact both clinically and socially. New treatment options are necessary in Iran due to issues with tolerance, interactions, contraindications, and the lack of ...
Seyed-Amirabbas Ahadiat, Zeinab Hosseinian   +1 more
doaj   +1 more source

Headache: Treatment update

eNeurologicalSci, 2022
Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high burden of migraine in terms of disability, there has been an effort to develop migraine specific therapies that has led to the ...
Oyindamola I. Ogunlaja, Peter J. Goadsby
doaj   +1 more source

Comparative efficacy, safety, and number needed to treat analysis of atogepant and rimegepant for the preventive treatment of episodic migraine in Japanese participants: An indirect comparison analysis

Cephalalgia Reports
Background In the absence of head-to-head analyses, indirect treatment comparisons (ITCs) can be used for comparative treatment evaluations. A previous ITC of atogepant and rimegepant assessed outcomes from US trials for the preventive treatment of ...
Takao Takeshima, Yasuhiko Matsumori, Gina Ahmadyar, Pranav Gandhi, Kari Kelton, Toru Yamazaki, Karen Carr, Krisztian Nagy, Jessica Ailani   +8 more
doaj   +1 more source

CGRP‐Targeted Therapy in Vestibular Migraine—How Strong Is the Evidence?

European Journal of Neurology, Volume 33, Issue 7, July 2026.
ABSTRACT Background Medications for migraine prevention targeting the calcitonin gene‐related peptide (CGRP) pathway have substantially reduced symptom burden in many patients that have failed previous treatment strategies. In contrast, data on treatment response to monoclonal antibodies (mAbs) or small molecule receptor antagonists (gepants) in ...
Alexander Andrea Tarnutzer, Patricia Castro Abarca, Diego Kaski   +2 more
wiley   +1 more source